The therapy which could drastically shrivel the tumor while sparing adjoining healthy cells might ultimately be employed as a substitute to chemo, radiotherapy or surgical intervention.

Preliminary studies have indicated that the pill known as Olaparib, additionally could fight ovarian cancer.

Specialists state that it could be certified for usage in the subsequent couple of years. Researchers are hopeful to create a pill which could cure prostate, colon and skin tumors.

Approximately 1500 females are identified with heritable breast cancer on a yearly basis and around seven hundred new-fangled cases of heritable ovarian cancer crop up.

However, even as breast cancer outlook has seen a dramatic rise over the last three decades, the survival rates in case of ovarian cancer continue to remain pessimistic and austere. Merely, thirty-nine percent of women detected with ovarian cancer manage to survive 5 years later in comparison to eighty percent of women identified with breast cancer.

The study was conducted by British scientists from the Breakthrough Breast Cancer Research Unit, King’s College. With 111 female study entrants, the research was aimed at studying the impact of the medication on advanced heritable breast cancer or ovarian cancer types among whom chemo has fail to bring about any improvement.

This latest research has been printed in the journal ‘The Lancet’, indicates that the tumors showed dramatic shrivelling in size among forty percent of the breast cancer cases that had been administered a high dosage of the pill therapy.

Analogous outcomes were observed in thirty-three percent of the ovarian cancer cases offered elevated dosages. The therapy was capable of halting tumor advancement for a number of months.

In both the scenarios, minimal and insignificant side-effects associated with the use of the pill were cited like weariness and feeling nauseous.

Researchers state that the drug, called as PARP inhibitor has been found to target cancerous cells developing due to the flawed BRCA1, BRCA2 genes while causing no harm to cells in good health.

This translates to the fact that patients would develop lesser side-effects like feeling nauseous and exhaustion which they would have experienced as result of chemo or radiotherapy, wherein even the normal cells bear the brunt of the therapy.

The medication has been observed to block PARP enzyme that assists cells having flawed BRCA genes in surviving.

Helming the study, Dr. Andrew Tutt stated that this novel form of therapy is exhibiting immense potential as a treatment for cancer that has developed due to this explicit heritable flaw.

Dr. Tutt further added that it was noteworthy to spot Olaparib benefiting females having later staging of ovarian and breast cancer and who have been given numerous chemo medications. But, he added that it is crucial to bear in mind that this medication is yet in its nascent staging of development and additional scientific studies are necessary for an exhaustive evaluation of its potential as a permitted therapy.

Approximately three percent of the 46000 females identified with breast cancer yearly ail from a heritable type of the condition.

Inherited ovarian cancer constitutes ten percent of the 7000 new-fangled cases annually. The study additionally suggested that males who are carriers of the flawed gene have a 1 in fifteen likelihood of getting breast cancer when they are seventy years of age.

The tablet known as eirbulin has been found to add 2 to 2 ½ months to the life span of people due to face death due to breast cancer.

Presentation of the outcomes of a Phase Three study were made during a conference of the American Society of Clinical Oncology, Chicago which was conducted by Dr. Christopher Twelves from St. James Hospital, Leeds and a global group of researchers.

The study enrolled 762 people with breast cancer having diverse kinds of tumor and having cancer that had metastasized. These patients had undergone a minimal of duo chemo rounds. From the study entrants, 2/3rds were given duo eribulin dosages while being offered benchmark therapy, generally with another chemo drug however sporadically with merely palliative care for treating pains and other signs. The other one-third patients were given round 3 chemo or palliative care.

No sooner does this therapy meet with failure then such patients mostly face fatality.

But, the study entrants offered eribulin were found to do significantly better and classically survived for thirteen months in comparison to merely below eleven months in the case of the placebo group.

Dr. Twelves stated that till present times, there has not been any benchmark therapy for females having advanced staging breast cancer. In case of those females who have by then been given all the identified therapies, such study outcomes hold immense potential and a major advancement in the field of breast cancer research.

Majority of the cancer studies are on the lookout for advancement-free survivals which means that physicians are checking whether the tumors are showing re-growth or at times checking merely reaction rate for seeing whether any tumor shrinkage occurred. However, this trial evaluated the actual span of time that the cancer patients survived.

The medication functions on the analogous theory, yet with a slight variation in method as earlier medications known as taxanes and administered via the intravenous route. The novel medicine impersonates a constituent present in aquatic sponges that averts cell division.

Other specialists stated that eribulin could be among the final novel chemo medications that classically aim at swift developing cells which comprise of tumors however also normal cells.

In 3 other trials conducted, it was found that eribulin was effectual and had favourable tolerance levels among varied sets of patients having cancers of breast, colon and even urinary cancer.

The study authors point out that there is shortage of medications that exhibit a survival benefit in such scenarios and eribulin definitely hails in the era of targeted therapy and fresh lease to breast cancer research.

• Swelling or lumps that are usually though not pain-free at all times.
• Skin dimples or puckers.
• Nipples get retracted or turn inwards.
• Reddishness or scaling noted in the nipples or skin of the breast.
• Some form of emission or discharge from the nipples.

Although such changes are not caused due to cancer at all times. For instance, majority of the breast lump formations among males are because of gynaecomastia (a non-harmful swelling in tissue of the breast). Yet, in case a man notices some kind of change in the breasts then it is imperative to seek medical opinion as quickly as doable.

Symptoms of male breast cancer when detected early could improve likelihood of successful treatment.

How Male breast cancer Differs from Female Breast Cancer

There are several resemblances in-between breast cancer in males and females; however there are a few crucial differences in between the two which could have an effect on early detection of symptoms of male breast cancer.

Breast Size

The most apparent differentiating factor in-between men and women breasts are the size. Since males do not have much breast tissue hence even small-sized tumor or mass formations could be palpated with ease by the man and the health care expert. Conversely since males have a small amount of breast tissue, cancer would not need to metastasize too much for being able to reach the nipples. Hence, in spite of breast cancer among men have a tendency of being somewhat smaller in size in comparison to females when initially identified, they would have often metastasized to the adjacently placed lymph nodes or tissues. The extent of metastasis is one of the highly significant deciding factors in breast cancer outlook.

Dearth of Awareness

Another variation is that breast cancer is commonly found in females whereas rarely found among males. Females have a tendency of being wary about breast cancer and its likely caveat signs whereas majority of the males fail in realizing that they have even a miniscule possibility of being affected with this disease. A number of males tend to overlook breast lumps or are of the thought process that these lumps have developed due to an infection or some other cause. Men often fail to receive medical therapy till the mass has grown in size. Several males harbour feelings of embarrassment about locating a breast lump and are worried that their manliness might be questioned. Due to this reason, diagnosis often gets delayed because of which the man’s prospects of having a successful therapy also diminish as a consequence.

Breast cancer is analogous in both sexes yet it is more frequently hormone- receptor positive among males. Nearly ninety percent of all breast tumors among males are invasive form of cancers and the rest ten percent are non-invasive type. Nearly all non-invasive cancer types are DCIS (ductal carcinoma in situ) and are generally low to intermediary grade when located.

Breast Cancer Symptoms:

Changes that a woman should be vigilant about

It is imperative to seek medical opinion in case one has noticed any of the below mentioned signs which could be indicators of breast cancer symptoms.

• Formation of lump or lumps or region of tissue thickening in one or both breasts.
• Discharge being emanated from either one or both nipples that might be blood inundated and other than breast milk.
• Irritation, swelling of most parts of breast even in case no apparent lump is being sensed.
• Reddishness, peeling or thickening of nipples or breast skin.
• Lumps or swollen areas in one or both areas of the underarms.
• An alteration in the size or form of either one or both the breasts.
• The skin of the breast shows puckering or dimpling.
• Rashes developing on the nipple or around it.
• An alteration in the way the nipple appears like it would appear sunken or retracted into the breast.
• Pains felt in one or both breasts or underarm areas that are not associated with menstruation.

A lump formation in the breast might not be the outcome of breast cancer and almost ninety percent of breast lump cases are non-malignant or benign. Breast lumps could develop due to a non-harmful cyst (a tiny fluid inundated lump) or the prevalently occurring non-cancerous growths known as fibroadenoma. The breasts could additionally feel lump-like just prior to a woman’s menstrual periods.

A non-painful, hardened mass with uneven edges has greater likelihood of being malignant however breast cancer could be soft, smoothed or tender.

At times, a breast cancer could metastasize to the lymph nodes located in the armpits and causing breast cancer symptoms like swelling or lump formation in that area, even prior to the initial tumor in the breast tissue being of a size that is palpable.

However, in case one notices any alterations in one or both breasts as mentioned above then it is imperative to show them promptly to the doctor.

Despite extensive usage of screening mammograms have augmented the number of breast cancer cases detected prior to them becoming symptomatic, a number of breast cancers are not spotted even by mammograms, either due to the test not being performed or since even under normal conditions, a mammogram is not able to uncover every breast cancer.

Breast cancer has greater frequency of occurrence among particular racial populaces, though the true reasons why such disparities exist are still blurred. For investigating this matter, Lisa Hines from the Univ. of Colorado, Colorado Springs, helmed the research which took into consideration how ascertained breast cancer risk factors – inclusive of history (menstrual, family, reproductive), hormonal usage, height, BMI (Body mass index), alcohol intake, how physically active a person is – could be involved in elucidating a number of the noticed disparities in the incidence of breast cancer among ethnic sets.

The investigators examined females from South-West U.S. having breast cancer that were registered in the populace-based, case control 4-Corners Breast Cancer Study that were intended to scrutinize risk factors which were contributory to the differences in breast cancer occurrence rates noted in-between Spanish American and non-Spanish American white females.

Previous researches have indicated that non-Spanish American white females had an elevated frequency of breast cancer as compared to Spanish American females. During the course of the present study, the investigators observed that 62-75% of breast cancer cases in non-Spanish American white females were attributable to identified breast cancer risk factors in comparison to merely seven to thirty-seven percent of cases in Spanish American females. Spanish American females had a greater likelihood of having traits linked to lesser breast cancer risk like sooner age of foremost delivery, lesser alcohol intake. In females in their premenopause phase, taller stature and family past case of breast cancer were linked to augmented risk among non-Spanish American white females however were not noted in Spanish American females.

Among females in their post-menopause phase, particular breast cancer risk factors among non-Spanish American white females like latest hormone therapy usage and precocious menstruation or premature menarche had zilch or solely frail links with breast cancer in Spanish American females.

Such study outcomes indicate that several of the breast cancer risk factors researched till date explicate lesser of the breast cancer cases which occur in Spanish American females in comparison to non-Spanish American white females. Such disparities are likely contributors to differences in breast cancer occurrence rates and might potentially be reflective of the discrepancies in breast cancer growth in such racial sets. For instance, racial disparities in heritable, environmental or lifestyle aspects could have an effect on a person’s vulnerability to breast cancer development.

During the course of this latest study, researchers employed data taken from the large WHI or Women Health Initiative. They uncovered that the levels of marker EGFR (epidermal growth factor receptor) could shoot up in the blood samples of females before even seventeen months of their breast cancer diagnosis. Epidermal growth factor receptor is a marker that plays a vital role in the development and metastasis of breast cancer cells.

Study author, Dr. Christopher Li stated that on its own, epidermal growth factor receptor failed in proving to be beneficial as a marker for breast cancer identification.

Dr. Li who is an affiliate of the epidemiology program, Fred Hutchison Cancer Research Center, Seattle, further added that their objective was for developing a group of biomarkers which would be far more precise in breast cancer diagnosis.

High Levels of epidermal growth factor receptor Prior to Breast Cancer Diagnosis

The latest research involving 688 female entrants all having ER-positive or estrogen-receptor positive type of breast cancer and who had their blood samples taken in seventeen months before their breast cancer got diagnosed. The outcomes of blood analysis test of these women were contrasted against the 688 female study entrants that belonged to the analogous age bracket and that had not yet experienced any signs or symptoms of breast cancer.

A presentation of the study outcome was done during the American Association for Cancer Research yearly conference.

By and large, investigators of the study made an identification of seventy-nine proteins. The levels of these detected proteins were high in the blood sample of females having breast cancer in comparison to other females.

EGFR was one of these identified proteins which could be corroborated employing a commercially obtainable assay.

The investigators then segregated nearly four hundred of the females into 4 sets based on the levels of EGFR in their blood samples. Women in the highest sector were at a three-fold greater risk of getting breast cancer in comparison to women in the lowest quarter.

The investigators then solely scrutinized the EGFR levels amongst the approximately 150 women who were currently using estrogen plus progestin hormone treatment.

Dr. Li elucidated that it is well-known that hormone treatment considerably impacted amounts of proteins that circulated in the blood.

Those females belonging to the highest quarter were at a nine fold greater risk of getting breast cancer in comparison to women belonging to the lower quarter. Dr. Li further stated that the investigators are still not totally certain as to the reason behind hormone therapy having such a major effect.

As a sole marker amongst women currently using estrogen plus progestin hormone therapy, levels of EGFR were able to make a precise identification in ninety percent of females that would not get breast cancer.

However, EGFR levels were able to identify solely thirty-one percent of females that would get breast cancer.

Dr. Li stated that they are planning to evaluate whether a group of biomarkers could be merged with mammography which could augment the precision of the general screening strategy.

He further added that the upside to the research was that the investigators were able to use blood samples drawn from females before they were identified with breast cancer. He stated that when the blood samples are used after they have been detected and become symptomatic then it is usually quite late.

Having won Wimbledon Singles for 9 times, the champ expressed the reports as a tragedy with as much marring effects as that of the 9/11 attacks. After getting news of her diagnosis with breast cancer type DCIS during February, Navratilova stated that she wept inconsolably.

The over fifty year old tennis legend who has taken retirement from competitive tennis just 3 years back was in a state of utter disbelief and the news was nothing short of a bolt from the blue.

Navratilova unequivocally spoke about feeling completely inundated with grief and her life being way beyond her control.

She stated that in her impressive lengthy tennis career spanning decades, she has come across really hard-hitting contenders on the court like Seles, Steffi Graf, Serena and Venus Williams among several others.

Though what she never predicted was being faced with the strongest opponent off the net – cancer.

She added that she firstly received the reports of her being diagnosed with breast cancer type DCIS while she was by herself at her house and was taken aback, besieged and in a state of utter devastation.

What really stunned her was that despite being actively involved in the field of sports for all her life, having followed a healthful way of existence by eating right and being fit, yet she had developed the disease. Such favourable facets of her life only seemed to fuel nagging queries about ‘why it had to be me’ in the initial couple of days after getting the news.

However, she mentioned that in spite of the downside being that it was breast cancer – the positive aspect about it is was no apparent metastasis has occurred till then.

Having won the Grand Slam singles for eighteen times, Navratilova stated that her foremost thoughts on learning about having being diagnosed with cancer in the left breast were worries about disfigurement as opposed to fatality. She confessed about her worries about losing her breast and hair.

However, Navratilova’s gynaecologist, Dr. Mindy Nagle states that her case is the best-possible setting imaginable for identifying breast cancer. According to doctors options her chances of recovery are ideal since they have detected the cancer in its earlier staging.

Martina has DCIS (ductal carcinoma in situ) – a non-invasive type of breast cancer that had not yet spread past the breast tissues and was yet only present in the milk ducts.

Born in Czechoslovakia, Navratilova has been through a lumpectomy procedure in mid-March for excision of malignant tissues.

Just fourteen days after, she was an active participant in a triathlon and intends on commencing her radiation therapy while in Paris that would help her continue commentating while she treatment ensues.

She spoke about undergoing radiation treatment due to her breast cancer being of the grade three type which is believed to have greater aggressiveness.

Martina has insisted upon all women to undergo mammograms annually since by the time lumps develop, it would get quite late. She does hold herself responsible to a major extent to having postponed her mammogram screening for nearly four years.

Being attentive to the caveat signs of breast cancer could essentially aid in diagnosing this lethal disease and as a result save many lives.

As breast cancer is one of the increasingly widespread forms of cancer worldwide, hence it is crucial that all women become sentient about the caveat symptoms of breast cancer which would be helpful in early diagnosis.

1. Any Palpable lumps or thickening on the breast area or armpits

A woman could sense a number of bodily changes during the course of her monthly menstrual cycle that could be physically palpated. But, in case there is an abnormal lumpy formation or growths which a woman could palpate during any time of the month, then this is cause for concern and a caveat indication of breast cancer.

2. Noticeable or Palpable Changes in Breast

In case any difference is felt in the form, outline of the breast that could be either palpated or apparent, then it could most probably be an indication of breast cancer. No woman should ignore variations in the size, contour of the breast as these could be signs of underlying breast cancer.

3. Any atypical Painful sensation in Breasts or armpits

In case a woman senses pain that is atypical, continual or long-drawn-out painful sensation in the breasts or underarms must be carefully scrutinized as at times pains could be indicative of something not right, even though other breast cancer symptoms are not apparent.

4. Blood loss or emanation from the nipples

In case, one notices any form of emanation from the nipples appearing colourless, fluid-like consistency or blood being discharged from the nipples, then it might be a caution indication of breast cancer. Hence, any form of discharge from the nipples except for breast milk should be deemed serious.

5. Variation in outward appearance of the Breasts

In case the skin over the breasts are appearing coarse and flaking or peeling, in case the breast skin puckers or dimples, or some extent of reddishness or irritation is present or nipple is appearing to be pulled inward, then any of these could be suggestive of preliminary signs of breast cancer that must be evaluated medically as promptly as doable.

6. Variations in Bowel motions

In case a woman feels constipated, having loose bowels or other variations in bowel habits then it might be indicative of foremost symptoms of breast cancer.

7. Other Symptoms

The presence of an unremitting soreness that fails in healing soon or in case a woman senses some problem in ingestion, a sense of fullness felt despite not having eaten a complete meal or not eaten usual meal, niggling coughing or any variations in the outline and size in any mole or wart present in the body are all to be watched out for as any one of these could be the caveat symptoms of breast cancer.

The cancer staging depicts the extent and if the cancer has metastasized past its initial location. When doctors gain knowledge of the exact form and the staging of the cancer it assists them in deciding on the apt line of treatment.

Among a number of individuals the cancer could have metastasized to other areas of the body either making an entry into the blood or via the lymphatic system (the system that partly dons the role in the body’s safeguard from infection and ailment. The lymphatic system comprises of a net of lymph glands (nodes) which are interconnected via lymph fluid filled delicate ducts. The area adjacent to the lymph nodes would be examined for ascertaining the staging of the cancer.

A widely utilised staging system is illustrated below:

• Stage 1
  The tumor measuring below two centimetres in width. The lymph glands present in the underarm area have not yet shown the presence of the cancer and there are no evident indications of cancer having reached other areas of the body.
• Stage 2
  The tumor measuring two to five centimetres in width, or the lymph glands present in the axilla or underarm area are having the presence of cancer or both of these could occur. Yet, any further increase of the cancer is not seen.
• Stage 3
  The tumor is above five centimetres in width and could be affixed to the adjacent muscles or skin. The lymph glands would show the presence of the cancer, however the cancer has not yet reached further past the breast or the lymph glands present in the axilla.
• Stage 4
  Irrespective of the extent of the tumor, the cancer has reached the lymph glands and other areas of the body like the bone or lungs. This is known as secondary or metastatic breast cancer.

Grading

Grading depicts the microscopic form of the cancerous cells and offers information of the manner in which the cancer would progress. Grading is of three types:

• Grade 1 or low grade- indicating that the cancerous cells bear similarity to the healthy breast cells. Such cancerous cells are generally slow in growth and spreading.
• Grade 2 or moderate, intermediate grade.
• Grade 3 or high grade – The tumors appear anomalous have greater likelihood of swiftly growing and spreading.

Nearly ninety percent of all cases of breast cancer originate in the duct or lobe and about seventy-five percent of all breast cancers originate in the cell lining of the milk ducts and are known as ductal carcinoma. About thirty percent of male breast cancers are lobular carcinoma that originates in the lobules present in both the breasts.

A form of breast cancer that has metastasized beyond the ducts and into the adjacent tissues is known as IDC or infiltrating carcinoma that constitutes most of the male breast cancer cases. In case the cancer originates at the end of the duct, it is known as infiltrating lobular carcinoma – an atypical form of breast cancer.

Nearly one to five percent of all breast cancers are inflammatory breast cancer. Paget’s disease affecting the nipples originates in the duct; however reach the skin surface of the nipples. Paget’s disease is prevalent among males than females.

Male Breast Cancer would be diagnosed by undergoing a physical exam of the breast that has been doubted. Tests would be required for corroborating the analysis and for finding if the cancer has metastasized. Any or all of the following tests would be performed in that regard.

• Mammography
  An X-ray of the breast would be carried out for probing for any alterations in the breast, however ultrasound scans usually provide better diagnosis of breast cancer among males.
• Ultrasound
  Ultrasound scan employ sound waves for observing if the lump has a solid or fluid-like consistency. Prior to the commencement of the scan, a miniscule quantity of colourless gel is slathered over the breast following which a small-sized, mike-similar piece of equipment is stroked all over the breast area for revealing images of the inner parts of the breast viewed on the monitoring screen.
• Fine needle aspiration
  A delicate needle is introduced inside the breast till it reaches the lump site from where few cells would be extracted at the analogous time when the ultrasound is being performed in order to ensure that the cells belong to the malignant part of the breast. This cell sample is then sent for microscopic analysis to check for malignancy.
• Needle Biopsy Procedure
  A infinitesimal amount of tissue sample is removed from the breast using a fine needle for microscopically examining the extracted cells for malignancy. A local anaesthesia shot is administered for numbing the site prior to conducting biopsy.
• Blood Analysis
  A number of blood tests would be carried out for checking the overall health of the person.